Filing summary
Issuer discrepancy: The request identifies Scienture Holdings, Inc., but the supplied Form 10-K is for Trxade Group, Inc. (OTC ticker TRXD). This summary reflects the filing provided, for the fiscal year ended December 31, 2017; it is an annual report, not a quarterly filing.
Business context and reporting period
Trxade operates a U.S. business-to-business online pharmaceutical marketplace connecting independent pharmacies and pharmaceutical suppliers. It generally earns transaction fees from sellers; substantially all 2017 revenue came from its Trxade.com platform. The company reported more than 8,500 registered pharmacy members and over 25 supplier relationships. InventoryRx, Pharmabayonline and RxGuru had not generated revenue as of the filing.
Westminster Pharmaceuticals, the company’s unprofitable private-label distribution subsidiary, was sold on December 31, 2016 and is presented as discontinued operations. The 2017 results therefore principally reflect the continuing marketplace business.
Key financial metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $2.931 million | $2.482 million |
| Operating income (loss) | $395,095 | ($1.007 million) |
| Income (loss) from continuing operations | $288,983 | ($1.173 million) |
| Net income (loss), including discontinued operations | $288,983 | ($2.760 million) |
| Operating cash flow from continuing operations | $171,670 | ($503,529) |
| Cash and cash equivalents at year-end | $183,914 | $14,679 |
| Working capital | $82,119 | ($1.137 million) |
| Total liabilities | $929,409 | $1.485 million |
| Shareholders’ equity (deficit) | ($311,933) | ($1.148 million) |
Revenue increased about 18% year over year. Operating expenses were $2.536 million in 2017, including $2.268 million of general and administrative expense and $267,835 of warrant and option expense. Interest expense was $157,056. The resulting operating margin was approximately 13.5%, and net margin approximately 9.9%. The filing does not provide a separate gross-margin figure for continuing operations.
At December 31, 2017, current assets were $607,476 and current liabilities were $525,357. Short- and long-term debt totaled $666,516, including $262,464 due in 2018. Contractual obligations totaled $978,858, comprising debt and operating leases. The company reported no off-balance-sheet arrangements.
Material changes versus 2016
- The company moved from a continuing-operations loss of $1.173 million to income of $288,983, with higher platform revenue and lower general and administrative expense. Management attributed revenue growth partly to a greater mix of generic products, which carry higher fees, and customer acquisition efforts.
- General and administrative expense fell from $3.342 million to $2.268 million; management cited lower employee cash compensation as the platform moved into an operational phase.
- Cash from continuing operations turned positive, and year-end cash rose by $169,235. Financing cash flow was slightly negative after substantial debt repayments, despite new equity and related-party borrowing.
- The 2016 comparative includes Westminster’s discontinued-operation loss and sale gain; those items did not recur in 2017.
- Debt was restructured and some short-term obligations were extended. Related-party long-term debt stood at $222,552 at year-end, in addition to convertible and other debt.
Outlook, risks, contingencies and unusual items
- Management’s 2018 priorities were further platform development, customer growth and revenue expansion. It estimated approximately $2.975 million of operating expenses and working-capital needs over the next 12 months and said it expected to seek additional funding. It gave no revenue or earnings guidance and cautioned that financing may not be available on favorable terms or at all.
- The filing says the substantial doubt about the company’s ability to continue as a going concern disclosed for 2016 was resolved based on 2017 operations, capital raised and debt restructuring. However, management also says additional funding is needed and future positive cash flow or financing is not assured.
- Key business risks include pharmaceutical distribution regulation, changes to state rules governing pharmacy-to-pharmacy trading, supplier or buying-group concentration, competition from much larger distributors, and product, fulfillment, credit and counterfeit-drug risks. Two customers each represented more than 10% of revenue in both years.
- Disclosure controls and internal control over financial reporting were assessed as ineffective at year-end 2017. Reported material weaknesses included manual financial reporting processes, insufficient segregation of duties and inadequate written accounting and reporting procedures. The auditor did not provide an internal-control attestation.
- A class-action “junk fax” matter was settled for $200,000; final judgment and payment occurred in March 2017. The company said it believed other ordinary-course legal matters would not materially affect its financial position, results or cash flows.
- Related-party financing and governance merit attention: founders and executives provided loans, and the CEO and president together beneficially owned over 80% of common shares according to the filing. The company also had outstanding warrants and options that could dilute shareholders.
- The common stock was thinly traded on the OTC market, with penny-stock restrictions and no assurance of liquidity. The company had never paid dividends and did not expect to do so in the foreseeable future.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Trxade Group, Inc., not Scienture Holdings, Inc.
- Reconcile the reported $288,983 profit and $171,670 operating cash flow with the company’s modest cash balance, negative shareholders’ equity and $666,516 debt obligations.
- Review debt maturities, extensions and subsequent payments, particularly related-party notes and amounts due in 2018.
- Assess whether platform growth, customer concentration and supplier retention support sustainable revenue and cash generation.
- Track remediation of the disclosed material weaknesses and whether internal controls become effective.
- Evaluate potential dilution from outstanding warrants and options, insider control, related-party dealings and the stock’s limited OTC liquidity.